Covidien (NYSE:COV) named Stacy Enxing Seng president of its $1.4 billion global vascular therapies business.
Enxing Seng, 47, will lead the division’s 4,000 employees, reporting to Peter Wehrly, president of the Mansfield, Mass.-based firm’s respiratory & monitoring solutions and vascular therapies division. She joined Covidien in July 2010 after the company spent $2.6 billion acquiring ev3 and its Pipeline embolization treatment for cerebral aneurysms.
Enxing Seng was a founding member of ev3 and led its peripheral vascular division, according to a press release.
Last week, Covidien made CEO Joe Almeida chairman of the board and tapped former Bayer Healthcare chief Mark Trudeau to lead its pharmaceuticals division ahead of a planned spinout.
Aethlon Medical sets up advisory board
Aethlon Medical (OTC:AEMD) established an extracorporeal therapy scientific advisory board "to guide the advancement of the Aethlon Hemopurifier and other therapies developed from the Aethlon ADAPT system," saying it plans to add other advisory boards this year. Read more